Last reviewed 2026-06-01 · How we verify

Norden (OCTOPAMINE)

FDA-approved active Small molecule ✓ Verified Jun 2026

Norden (generic name: OCTOPAMINE) is a octopamine drug. It is currently FDA-approved.

Norden works by binding to the 5-hydroxytryptamine receptor 3A, a subtype of serotonin receptor.

Norden, also known as OCTOPAMINE, is a small molecule octopamine drug targeting the 5-hydroxytryptamine receptor 3A. Its mechanism of action and commercial status are not well-documented. As a result, there is limited information available on its approved indications, half-life, bioavailability, generic manufacturers, and off-patent status. Further research is needed to understand the pharmacological properties and clinical applications of Norden. Its development and current ownership are also unclear.

At a glance

Generic name	OCTOPAMINE
Drug class	octopamine
Target	5-hydroxytryptamine receptor 3A, Trace amine-associated receptor 1, Trace amine-associated receptor 1
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved

Mechanism of action

Imagine your brain has many locks on it, and serotonin is the key that fits into some of those locks. Norden is a special key that fits into one of those locks, called the 5-hydroxytryptamine receptor 3A, which helps regulate various bodily functions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Norden CI brief — competitive landscape report
Norden updates RSS · CI watch RSS

Frequently asked questions about Norden

What is Norden?

Norden (OCTOPAMINE) is a octopamine drug.

How does Norden work?

Norden works by binding to the 5-hydroxytryptamine receptor 3A, a subtype of serotonin receptor.

What is the generic name of Norden?

OCTOPAMINE is the generic (nonproprietary) name of Norden.

What drug class is Norden in?

Norden belongs to the octopamine class. See all octopamine drugs at /class/octopamine.

What development phase is Norden in?

Norden is FDA-approved (marketed).

What does Norden target?

Norden targets 5-hydroxytryptamine receptor 3A, Trace amine-associated receptor 1, Trace amine-associated receptor 1 and is a octopamine.

Drug class: All octopamine drugs
Target: All drugs targeting 5-hydroxytryptamine receptor 3A, Trace amine-associated receptor 1, Trace amine-associated receptor 1
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing